RxDoctor Payments Data

Leticia Wandler

Nurse Practitioner · Milwaukee, WINPI 1376147397

Payments from drug & device makers

$3,475in general payments, 2019–2025

Across 54 payments — averaging $64.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Boehringer Ingelheim$828
  • Sanofi$641
  • Pulmonx Corporation$166
  • United Therapeutics Corporation$156
  • GSK$125
  • plus $335 from 4 others

What the payments were for

  • Food & beverage$3,45299%
  • Education$231%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,475 in reported general payments places this provider in the 95th percentile of 3,478 nurse practitioner providers in Wisconsin.

See all nurse practitioner providers in Wisconsin

Medicare billing

Part B allowed, 2024
$8,406
Medicare patients
69
Services billed
107

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter134$99,919
Spiriva RespimatTiotropium Bromide86$58,366
Spiriva HandihalerTiotropium Bromide67$48,242
Advair HfaFluticasone Propion/Salmeterol94$46,018
Breztri AerosphereBudesonide/Glycopyr/Formoterol44$35,053
SymbicortBudesonide/Formoterol Fumarate90$32,924
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr59$30,552
Stiolto RespimatTiotropium Br/Olodaterol Hcl42$28,022
Incruse ElliptaUmeclidinium Bromide56$23,226
Breo ElliptaFluticasone/Vilanterol36$19,175
Fluticasone-SalmeterolFluticasone Propion/Salmeterol97$12,242
Wixela InhubFluticasone Propion/Salmeterol43$5,584
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate36$4,762
Arnuity ElliptaFluticasone Furoate18$4,514
Qvar RedihalerBeclomethasone Dipropionate14$4,125

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta, Breo Ellipta, Arnuity Ellipta$125$177,386303 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat$828$86,388128 claims
AstraZenecaBreztri Aerosphere, Symbicort$1,224$67,977134 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,478 nurse practitioner providers in Wisconsin.

Other nurse practitioner in Milwaukee

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →